Extended Data Fig. 4: Immune-mediated adverse events. | Nature Cancer

Extended Data Fig. 4: Immune-mediated adverse events.

From: Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial

Extended Data Fig. 4: Immune-mediated adverse events.The alternative text for this image may have been generated using AI.

Nivolumab plus ipilimumab arm, n = 282; nivolumab arm, n = 318; durvalumab arm, n = 317. Immune-mediated AEs were AEs consistent with an immune-mediated mechanism or an immune-mediated component for which noninflammatory etiologies (eg, infection or tumor progression) were ruled out. aAll-cause pneumonitis included pneumonitis, immune-mediated lung diseases, and interstitial lung disease. One grade 5 pneumonitis event was reported in the nivolumab alone arm.

Source data

Back to article page